Diabetic Peripheral Neuropathy - Pipeline Review, H2 2018

Diabetic Peripheral Neuropathy - Pipeline Review, H2 2018


  • Products Id :- GMDHC10648IDB
  • |
  • Pages: 65
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Diabetic Peripheral Neuropathy-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy-Pipeline Review, H2 2018, provides an overview of the Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline landscape.

"Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legsand feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain ordiscomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tonein the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes,smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics."

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Peripheral Neuropathy-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 8, 2 and 7 respectively.

Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Diabetic Peripheral Neuropathy-Overview

Diabetic Peripheral Neuropathy-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Diabetic Peripheral Neuropathy-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Peripheral Neuropathy-Companies Involved in Therapeutics Development

Achelios Therapeutics Inc

Commence Bio Inc

Grunenthal GmbH

Immune Pharmaceuticals Inc

Medifron DBT Co Ltd

Mitsubishi Tanabe Pharma Corp

Novaremed Ltd

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

Sphaera Pharma Pte Ltd

ViroMed Co Ltd

Diabetic Peripheral Neuropathy-Drug Profiles

(amitriptyline + ketamine hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diclofenac sodium + triclocarban)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AAD-2004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atexakin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNV-222-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNV-2197944-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

donaperminogene seltoplasmid-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketoprofen-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KU-32-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-16523-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-652-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSC-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-8554-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRD-135SE1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PDA-002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pirenzepine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Pain-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block CACNA1H for CNS Disorders, Toxicology and Metabolic Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium nitrite SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Diabetic Peripheral Neuropathy-Dormant Projects

Diabetic Peripheral Neuropathy-Discontinued Products

Diabetic Peripheral Neuropathy-Product Development Milestones

Featured News & Press Releases

Apr 12, 2018: AARP Calls ViroMed's VM202 Hope for Peripheral Neuropathy

Oct 30, 2017: VM BioPharma Announces Generic Name donaperminogene seltoplasmid for Investigational Novel Gene Therapy, VM202

Sep 25, 2017: ViroMed, Gene Therapy Powerhouse on Global Stage

Sep 08, 2016: ViroMed proceeding with the World's first phase III gene therapy clinical trial for diabetic peripheral neuropathy

Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy

Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Diabetic Peripheral Neuropathy-Pipeline by Achelios Therapeutics Inc, H2 2018

Diabetic Peripheral Neuropathy-Pipeline by Commence Bio Inc, H2 2018

Diabetic Peripheral Neuropathy-Pipeline by Grunenthal GmbH, H2 2018

Diabetic Peripheral Neuropathy-Pipeline by Immune Pharmaceuticals Inc, H2 2018

Diabetic Peripheral Neuropathy-Pipeline by Medifron DBT Co Ltd, H2 2018

Diabetic Peripheral Neuropathy-Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018

Diabetic Peripheral Neuropathy-Pipeline by Novaremed Ltd, H2 2018

Diabetic Peripheral Neuropathy-Pipeline by Reata Pharmaceuticals Inc, H2 2018

Diabetic Peripheral Neuropathy-Pipeline by Relief Therapeutics Holding AG, H2 2018

Diabetic Peripheral Neuropathy-Pipeline by Sphaera Pharma Pte Ltd, H2 2018

Diabetic Peripheral Neuropathy-Pipeline by ViroMed Co Ltd, H2 2018

Diabetic Peripheral Neuropathy-Dormant Projects, H2 2018

Diabetic Peripheral Neuropathy-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Achelios Therapeutics Inc

Commence Bio Inc

Grunenthal GmbH

Immune Pharmaceuticals Inc

Medifron DBT Co Ltd

Mitsubishi Tanabe Pharma Corp

Novaremed Ltd

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

Sphaera Pharma Pte Ltd

ViroMed Co Ltd

Diabetic Peripheral Neuropathy Therapeutic Products under Development, Key Players in Diabetic Peripheral Neuropathy Therapeutics, Diabetic Peripheral Neuropathy Pipeline Overview, Diabetic Peripheral Neuropathy Pipeline, Diabetic Peripheral Neuropathy Pipeline Assessment

select a license
Single User License
USD 2000 INR 141960
Site License
USD 4000 INR 283920
Corporate User License
USD 6000 INR 425880

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com